APA (7th ed.) Citation

SK, M., M, K., KF, B., A, D., MCW, W., SK, S., . . . IM, S. (2022). Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma. Oncoimmunology, 11(1), 2023255. https://doi.org/10.1080/2162402X.2021.2023255

Chicago Style (17th ed.) Citation

SK, Mørk, et al. "Personalized Therapy with Peptide-based Neoantigen Vaccine (EVX-01) Including a Novel Adjuvant, CAF®09b, in Patients with Metastatic Melanoma." Oncoimmunology 11, no. 1 (2022): 2023255. https://doi.org/10.1080/2162402X.2021.2023255.

MLA (9th ed.) Citation

SK, Mørk, et al. "Personalized Therapy with Peptide-based Neoantigen Vaccine (EVX-01) Including a Novel Adjuvant, CAF®09b, in Patients with Metastatic Melanoma." Oncoimmunology, vol. 11, no. 1, 2022, p. 2023255, https://doi.org/10.1080/2162402X.2021.2023255.